BMS Ties Up With Simcere To Commercialize Orencia SC In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Looking for differentiated products in an increasingly tough pricing environment, Simcere will help Bristol bring its first biologic to China.
You may also be interested in...
China's Simcere Beats Out Eisai In Iguratimod Approval For Rheumatoid Arthritis
SHANGHAI- China's State FDA cleared Simcere Pharmaceutical Group's new drug application for Iremod (iguratimod) for rheumatoid arthritis, in the world's first approval of the compound, Simcere announced Aug. 25
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.